Current Report Filing (8-k)
14 June 2023 - 8:02PM
Edgar (US Regulatory)
0001716947
false
0001716947
2023-06-13
2023-06-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 13, 2023 (June 13, 2023)
Ensysce
Biosciences, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-38306 |
|
82-2755287 |
(State
or other jurisdiction of
incorporation
or organization) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
7946
Ivanhoe Avenue, Suite 201
La
Jolla, California |
|
92037 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(858)
263-4196
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
ENSC |
|
The
Nasdaq Stock Market LLC |
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01 Other Events.
On
June 13, 2023, Ensysce Biosciences, Inc. (the “Company”) was formally
notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has
regained compliance with the equity requirement in Nasdaq Listing Rule 5550(b)(1) and that the matter before the Nasdaq Hearings Panel
concerning the Company’s compliance with Nasdaq listing requirements has been closed. Although the Company’s securities may
continue to be listed on Nasdaq, Nasdaq stated that the Company must remain in compliance with all of Nasdaq’s listing requirements.
There can be no assurance that the Company will be able to maintain compliance with all of Nasdaq’s listing requirements in the
future.
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
June 13, 2023
|
Ensysce
Biosciences, Inc. |
|
|
|
|
By: |
/s/
Lynn Kirkpatrick |
|
Name:
|
Dr.
Lynn Kirkpatrick |
|
Title: |
President
and Chief Executive Officer |
Ensysce Biosciences (NASDAQ:ENSC)
Historical Stock Chart
From May 2024 to Jun 2024
Ensysce Biosciences (NASDAQ:ENSC)
Historical Stock Chart
From Jun 2023 to Jun 2024